Introduction: Bladder cancer is the ninth common cause of cancers in both sexes worldwide. Nevertheless, little is known about the descriptive and analytic epidemiology of bladder cancer in Iran. The present study aimed to describe the nationwide distribution of death due to bladder cancer in Iran.
Methods: This cross-sectional study used data of bladder cancer cases who were registered in the national cancer-registry system by the Ministry of Health and Medical Education during 2001-2007. Age-standardized mortality rates due to bladder cancer were presented according to nine geographic poles across the country.
Results: The overall mortality rate of bladder cancer (per 100,000 population) was 2.26 in men and 1.36 in women; while the rates were constantly higher for men across all age groups. The highest and lowest age-standardized mortality rates in provinces (per 100,000 population) belonged to Mazandaran (6.126) and Tehran (1.112), respectively.
Conclusion: Death from bladder cancer seems to increase by age in Iran, mainly among men. This association might be partially due to increased life expectancy, altered high-risk lifestyle behaviors and/or improvement in cancer registration system. Information on the distribution of mortality due to bladder cancer could be useful for local prevention strategies, where specific profile of communities and patients is taken into account.
Esmail Nasab N, Moradi G, Zareie M, Ghaderi E, Gheytasi B. Survey of epidemilogic status and incidence rates of cancers in the patients above 15 years old in Kurdistan province. Scientific Journal of Kurdistan Uni-versity of Medical Sciences. 2007;11(4):18-25.
Cumberbatch MGK, Jubber I, Black PC, Esperto F, Figueroa JD, Kamat AM, et al. Epidemiology of bladder cancer: a systematic review and contemporary update of risk factors in 2018. European urology. 2018.
Mohammad-Beigi A, Rezaeeianzadeh A, Tabbat-abaei HR. Application of life table in survival analysis of patients with bladder cancer. Zahedan Journal of Re-search in Medical Sciences. 2011;13(3):25-9.
Allameh F, Fallah Karkan M, Nilipour Y, Rakhshan A. Primary signet-ring cell carcinoma of the urinary bladder successfully managed with radical cys-tectomy in a young patient. Case reports in urology. 2017;2017.
Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA: a cancer journal for clinicians. 2011;61(2):69-90.
Chavan S, Bray F, Lortet-Tieulent J, Goodman M, Jemal A. International variations in bladder cancer inci-dence and mortality. European urology. 2014;66(1):59-73.
Hassan TM, Al-Zahrani I. Bladder cancer: Analy-sis of the 2004 WHO classification in conjunction with pathological and geographic variables. African Journal of Urology. 2012;18(3):118-23.
Fedewa SA, Soliman AS, Ismail K, Hablas A, Seifeldin IA, Ramadan M, et al. Incidence analyses of bladder cancer in the Nile delta region of Egypt. Cancer epidemiology. 2009;33(3-4):176-81.
Burger M, Catto JW, Dalbagni G, Grossman HB, Herr H, Karakiewicz P, et al. Epidemiology and risk fac-tors of urothelial bladder cancer. European urology. 2013;63(2):234-41.
Ploeg M, Aben KK, Kiemeney LA. The present and future burden of urinary bladder cancer in the world. World journal of urology. 2009;27(3):289-93.
Colombel M, Soloway M, Akaza H, Böhle A, Palou J, Buckley R, et al. Epidemiology, staging, grading, and risk stratification of bladder cancer. european urolo-gy supplements. 2008;7(10):618-26.
Keyghobadi N, Rafiemanesh H, Mohammadian-Hafshejani A, Enayatrad M, Salehiniya H. Epidemiology and trend of cancers in the province of Kerman: south-east of Iran. Asian Pac J Cancer Prev. 2015;16(4):1409-13.
Parizadeh D, Momenan AA, Amouzegar A, Azizi F, Hadaegh F. Tobacco Smoking: Findings from 20 Years of the Tehran Lipid and Glucose Study. . Int J Endocrinol Metab. 2018;16(4 Suppl):e84738. Published 2018 Oct 31. doi:10.5812/ijem.84738.
Khosravi A, Emamian MH, Hashemi H, Fotouhi A. Transition in tobacco use stages and its related factors in a longitudinal study. . Environ Health Prev Med 2018;23(1):39. Published 2018 Aug 18. doi:10.1186/s12199-018-0728-x.
Nakai Y, Nonomura N, Kawashima A, Mukai M, Nagahara A, Nakayama M, et al. Tumor multiplicity is an independent prognostic factor of non-muscle-invasive high-grade (T1G3) bladder cancer. Japanese journal of clinical oncology. 2009;40(3):252-7.
Pakzad R, Mohammadian-Hafshejani A, Mo-hammadian M, Pakzad I, Safiri S, Khazaei S, et al. Inci-dence and mortality of bladder cancer and their relation-ship with development in Asia. Asian Pacific Journal of Cancer Prevention. 2015;16(16):7365-74.
Zhang L, Wu B, Zha Z, Qu W, Zhao H, Yuan J. Clinicopathological factors in bladder cancer for cancer-specific survival outcomes following radical cystecto-my: a systematic review and meta-analysis. BMC cancer. 2019;19(1):716.
Mahdavifar N, Ghoncheh M, Pakzad R, Momen-imovahed Z, Salehiniya H. Epidemiology, incidence and mortality of bladder cancer and their relationship with the development index in the world. Asian Pacific Journal of Cancer Prevention. 2016;17(1):381-6.